专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1442052A1 HIGH LEVEL CONSTITUTIVE PRODUCTION OF ANTHRAX PROTECTIVE ANTIGEN 有权
标题翻译： HEIGHT炭疽构成生产表面保护抗原的
公开(公告)号：EP1442052A1
公开(公告)日：2004-08-04
申请号：EP01274653.3
申请日：2001-12-07
申请人： Bhatnagar, Rakesh , Waheed, Syed Moshin , Chauhan, Vibha
发明人： Bhatnagar, Rakesh , Waheed, Syed Moshin , Chauhan, Vibha
IPC分类号： C07K14/32
CPC分类号： C07K14/32
摘要： The present invention relates to a process for preparing anthrax protective antigen protein from E. coli using fed batch culture. This process creates a constitutively expressing system for rapid, efficient, cost-effective and high-level production of anthrax PA from E. coli. The steps of the process involves, transforming E. coli DH5alpha cells with the recombinant constitutive expression plasmid containing the PA gene to obtain recombinant DH5alpha cells and testing the PA expression by lysis of said cells followed by denaturing gel electrophoresis and Western Blotting technique using PA antibodies. This is followed by fermentation and harvesting of the high cell density cells. The said cells are solubilized using 6-8 Molar Urea and separated by centrifugation. The urea denatured PA is isolated from said supernatant and purified and thereafter eluted.

2. 发明专利

IN190590B A process for constitutively preparing anthrax protective antigen 未知
公开(公告)号：IN190590B
公开(公告)日：2003-08-09
申请号：IN1127DE2001
申请日：2001-11-05
申请人： BHATNAGAR RAKESH , WAHEED SYED MOHSIN , CHAUHAN VIBHA
发明人： BHATNAGAR RAKESH , WAHEED SYED MOHSIN , CHAUHAN VIBHA
IPC分类号： C12P21/02 , A61K39/07 , A61P31/04 , C07K20060101 , C07K14/32 , C12N1/21 , C12P21/00 , C12R1/07 , A61K39/00 , A61P43/00
摘要： The present invention relates to a process for preparing anthrax protective antigen protein from E. coli using fed batch culture. This process creates a constitutively expressing system for rapid, efficient, cost-effective and high-level production of anthrax PA from E. coli. The steps of the process involves, transforming E. coli DH5alpha cells with the recombinant constitutive expression plasmid containing the PA gene to obtain recombinant DH5alpha cells and testing the PA expression by lysis of said cells followed by denaturing gel electrophoresis and Western Blotting technique using PA antibodies. This is followed by fermentation and harvesting of the high cell density cells. The said cells are solubilized using 6-8 Molar Urea and separated by centrifugation. The urea denatured PA is isolated from said supernatant and purified and thereafter eluted.

3. 发明专利

CA2465679A1 HIGH LEVEL CONSTITUTIVE PRODUCTION OF ANTHRAX PROTECTIVE ANTIGEN 未知
公开(公告)号：CA2465679A1
公开(公告)日：2003-05-15
申请号：CA2465679
申请日：2001-12-07
申请人： BHATNAGAR RAKESH , WAHEED MOHSIN SYED , CHAUHAN VIBHA
发明人： BHATNAGAR RAKESH , WAHEED MOHSIN SYED , CHAUHAN VIBHA
IPC分类号： C12P21/02 , A61K39/07 , A61P31/04 , C07K20060101 , C07K14/32 , C12N1/21 , C12P21/00 , C12R1/07
摘要： The present invention relates to a process for preparing anthrax protective antigen protein from E.coli using fed batch culture. This process creates a constitutively expressing system for rapid, efficient, cost-effective and hi gh- level production of anthrax PA from E.coli. The steps of the process involve s, transforming E.coli DH5.alpha. cells with the recombinant constitutive expression plasmid containing the PA gene to obtain recombinant DH5.alpha. cells and testing the PA expression by lysis of said cells followed by denaturing gel electrophoresis and Western Blotting technique using PA antibodies. This is followed by fermentation and harvesting of the high cell density cells. The said cells are solubilized using 6-8 Molar Urea and separated by centrifugation. The urea denatured PA is isolated from said supernatant and purified and thereafter eluted.

4. 发明申请

WO2021262985A1 CYTOKINE CONJUGATES 审中-公开
公开(公告)号：WO2021262985A1
公开(公告)日：2021-12-30
申请号：PCT/US2021/038909
申请日：2021-06-24
申请人： AMUNIX PHARMACEUTICALS, INC. , SCHELLENBERGER, Volker , JOHANSEN, Eric , HENKENSIEFKEN, Angela , IRVING, Bryan , YOUNG, Tracy , CHAUHAN, Vibha , YEUNG, Valentine
发明人： SCHELLENBERGER, Volker , JOHANSEN, Eric , HENKENSIEFKEN, Angela , IRVING, Bryan , YOUNG, Tracy , CHAUHAN, Vibha , YEUNG, Valentine
IPC分类号： A61K38/17 , C07K1/12 , A61K47/50 , A61K47/64 , A61K49/00 , A61P35/00
摘要： The present invention relates to compositions comprising biologically active proteins, such as cytokines, linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of related disorders and conditions.

5. 发明申请

WO2003048390A1 A PROCESS FOR THE PREPARATION OF A NON-TOXIC ANTHRAX VACCINE 审中-公开
标题翻译：制备非毒性ANTHRAX疫苗的方法
公开(公告)号：WO2003048390A1
公开(公告)日：2003-06-12
申请号：PCT/IN2002/000048
申请日：2002-03-20
申请人： BHATNAGAR, Rakesh , GUPTA, Pankaj , BATRA, Smriti , CHAUHAN, Vibha , SINGH, Aparna , AHUJA, Nidhi , KUMAR, Praveen
发明人： BHATNAGAR, Rakesh , GUPTA, Pankaj , BATRA, Smriti , CHAUHAN, Vibha , SINGH, Aparna , AHUJA, Nidhi , KUMAR, Praveen
IPC分类号： C12Q1/68
CPC分类号： C07K14/32 , A61K39/00
摘要： Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B.anthracis . Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF or EF are incorporated into the vaccines. An ideal vaccine against anthrax should contain PA, LF and EF together, but this combination would be toxic. Therefore, the biologically inactive mutant preparations of PA, LF and EF may be used together for better immunoprotection. The present invention describes the method for generation of recombinant vaccine against anthrax, comprising of non-toxic, mutant anthrax toxin proteins. The procedure involves site-directed mutagenesis of the native genes of the toxin proteins, the expression and purification of the mutant proteins and finally characterization of these proteins.
摘要翻译：由保护性抗原（PA），致死因子（LF）和水肿因子（EF）组成的炭疽毒素是甘蓝的主要毒性因子。保护性抗原，PA是所有针对炭疽疫苗的主要成分。如果将小量的LF或EF并入疫苗中，则PA的保护功效大大增加。针对炭疽的理想疫苗应包含PA，LF和EF，但这种组合是有毒的。因此，PA，LF和EF的生物活性突变体制剂可以一起用于更好的免疫保护。本发明描述了用于产生针对炭疽的重组疫苗的方法，其包含无毒的突变体炭疽毒素蛋白质。该方法涉及毒素蛋白质的天然基因的定点突变，突变蛋白的表达和纯化以及这些蛋白质的最终表征。

6. 发明申请

WO03048390A8 A PROCESS FOR THE PREPARATION OF A NON-TOXIC ANTHRAX VACCINE 审中-公开
标题翻译：制备非毒性ANTHRAX疫苗的方法
公开(公告)号：WO03048390A8
公开(公告)日：2004-02-05
申请号：PCT/IN0200048
申请日：2002-03-20
申请人： BHATNAGAR RAKESH , GUPTA PANKAJ , BATRA SMRITI , CHAUHAN VIBHA , SINGH APARNA , AHUJA NIDHI , KUMAR PRAVEEN
发明人： BHATNAGAR RAKESH , GUPTA PANKAJ , BATRA SMRITI , CHAUHAN VIBHA , SINGH APARNA , AHUJA NIDHI , KUMAR PRAVEEN
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61K39/07 , A61P31/04 , A61P37/02 , C07K2/00 , C07K14/32 , C07K19/00 , C12N1/21 , C12N15/31 , C12N15/70 , C12P21/02
CPC分类号： C07K14/32 , A61K39/00
摘要： Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B.anthracis. Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF or EF are incorporated into the vaccines. An ideal vaccine against anthrax should contain PA, LF and EF together, but this combination would be toxic. Therefore, the biologically inactive mutant preparations of PA, LF and EF may be used together for better immunoprotection. The present invention describes the method for generation of recombinant vaccine against anthrax, comprising of non-toxic, mutant anthrax toxin proteins. The procedure involves site-directed mutagenesis of the native genes of the toxin proteins, the expression and purification of the mutant proteins and finally characterization of these proteins.
摘要翻译：由保护性抗原（PA），致死因子（LF）和水肿因子（EF）组成的炭疽毒素是甘蓝的主要毒性因子。保护性抗原，PA是所有针对炭疽疫苗的主要成分。如果将小量的LF或EF并入疫苗中，则PA的保护功效大大增加。针对炭疽的理想疫苗应包含PA，LF和EF，但这种组合是有毒的。因此，PA，LF和EF的生物活性突变体制剂可以一起用于更好的免疫保护。本发明描述了用于产生针对炭疽的重组疫苗的方法，其包含无毒的突变体炭疽毒素蛋白质。该方法涉及毒素蛋白质的天然基因的定点突变，突变蛋白的表达和纯化以及这些蛋白质的最终表征。

7. 发明申请

WO2003040179A1 HIGH LEVEL CONSTITUTIVE PRODUCTION OF ANTHRAX PROTECTIVE ANTIGEN 审中-公开
标题翻译： ANTHRAX保护性抗原的高水平生产
公开(公告)号：WO2003040179A1
公开(公告)日：2003-05-15
申请号：PCT/IN2001/000215
申请日：2001-12-07
申请人： BHATNAGAR, Rakesh , WAHEED, Syed, Mohsin , CHAUHAN, Vibha
发明人： BHATNAGAR, Rakesh , WAHEED, Syed, Mohsin , CHAUHAN, Vibha
IPC分类号： C07K14/32
CPC分类号： C07K14/32
摘要： The present invention relates to a process for preparing anthrax protective antigen protein from E.coli using fed batch culture. This process creates a constitutively expressing system for rapid, efficient, cost-effective and high-level production of anthrax PA from E.coli . The steps of the process involves, transforming E.coli DH5α cells with the recombinant constitutive expression plasmid containing the PA gene to obtain recombinant DH5α cells and testing the PA expression by lysis of said cells followed by denaturing gel electrophoresis and Western Blotting technique using PA antibodies. This is followed by fermentation and harvesting of the high cell density cells. The said cells are solubilized using 6-8 Molar Urea and separated by centrifugation. The urea denatured PA is isolated from said supernatant and purified and thereafter eluted.
摘要翻译：本发明涉及使用补料分批培养从大肠杆菌制备炭疽病保护性抗原蛋白的方法。该过程创建了一种组成型表达系统，用于从大肠杆菌中快速，高效，成本有效和高水平地生产炭疽芽孢杆菌。该方法的步骤包括用包含PA基因的重组组成型表达质粒转化大肠杆菌DH5α细胞以获得重组DH5α细胞，并通过裂解所述细胞测试PA表达，然后通过变性凝胶电泳和Western Blotting技术使用 PA抗体。随后发酵和收获高细胞密度的细胞。所述细胞用6-8摩尔尿素溶解并通过离心分离。尿素变性PA从所述上清液中分离并纯化，然后洗脱。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式